-
Sciwind Biosciences’ Ecnoglutide Accepted for Review by China’s NMPA for Type 2 Diabetes
•
China-based Sciwind Biosciences Co., Ltd has announced that the National Medical Products Administration (NMPA) has accepted its market filing for the Category 1 product ecnoglutide. The targeted indication for this treatment is blood glucose control in adult patients with type 2 diabetes. Ecnoglutide’s Therapeutic Potential and Clinical Trial SuccessEcnoglutide is…
-
Three Senior Executives of Henan Topfond Pharmaceutical Under Investigation
•
On November 22, China General Technology (Group) Holding released three official announcements through its official channels, all concerning the investigation of senior executives at Henan Topfond Pharmaceutical Co., Ltd. (SHA: 600253). The details are as follows: Background on Henan Topfond PharmaceuticalEstablished in 1969, Henan Topfond Pharmaceutical is a large-scale comprehensive…
-
Leman Biotech Enters Zhongshan Life Science Park to Accelerate CAR-T Innovation
•
Innovative biotechnology company Leman Biotech, focused on cutting-edge cell therapy technology, has announced its official move to Zhongshan Life Science Park on November 21. This relocation marks a significant step forward in the development of a novel automated, fully enclosed CMC process for ultra-low dose CAR-T (chimeric antigen receptor T…
-
BRL Medicine Inc. Secures Nearly $30 Million in B+ Round Financing to Advance Pipeline
•
On November 22, 2024, BRL Medicine Inc. announced the completion of nearly 200 million yuan in B+ round financing. The round was led by CSCP Fund, with follow-on investments from institutions including Beta Fund. With this funding, BRL Medicine will accelerate the clinical translation and commercialization of its multi-pipeline products…
-
Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies
•
On November 22, 2024, B&K Corporation Limited (Bio-Bank Corp.), a biopharmaceutical company headquartered in China, has resubmitted its application for listing on the Hong Kong Stock Exchange (HKEX). The company is advised by joint sponsors Hua Tai International and CITIC Securities. Company Background and Therapeutic FocusFounded in 2012, Bio-Bank Corp.…
-
HutchMed Anticipates Milestone Payment as Takeda Launches Fruzaqla in Japan for CRC
•
China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a milestone payment from its partner Takeda (TYO: 4502), following the successful pricing approval and launch of Fruzaqla (fruquintinib) 1mg/5mg capsules in Japan. The drug is indicated for patients with previously treated metastatic colorectal cancer (CRC). Fruzaqla’s Approval…
-
First Patient Dosed in Abbisko’s Phase II Trial of ABSK061 and ABSK043 in FGFR2/3 Altered Tumors
•
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the first patient dosing in an open, multi-center Phase II study. The study is designed to assess the safety and efficacy of its investigational drugs ABSK061 combined with ABSK043, with or without chemotherapy, in patients with metastatic or unresectable solid…
-
Bayer’s Nubeqa Files for FDA Approval in mHSPC
•
German pharmaceutical company Bayer AG (ETR: BAYN) has announced that the US Food and Drug Administration (FDA) has accepted its supplemental new drug application (sNDA) for Nubeqa (darolutamide) for review. Bayer is seeking approval for its androgen receptor inhibitor (ARi) in combination with androgen deprivation therapy (ADT) for the treatment…
-
MSD China to Streamline Diabetes Business Amid Volume-Based Procurement Inclusion
•
The China unit of US pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) is reportedly streamlining its diabetes business through redundancies, according to local media outlet Yicai. This move is a response to the anticipated impact of the inclusion of its sitagliptin and other drugs in China’s volume-based…
-
Zai Lab Ltd Partners with Pfizer for Commercialization of Xacduro in China
•
China-based biotechnology company Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced a strategic collaboration agreement with global pharmaceutical giant Pfizer (NYSE: PFE). The partnership grants Pfizer’s affiliated companies the exclusive rights to commercialize Xacduro (durlobactam, sulbactam) in mainland China. This collaboration, set to be in effect through November 2028,…
-
China Grants Marketing Approval for MSD’s Welireg for von Hippel-Lindau Disease Tumors
•
China’s National Medical Products Administration has issued marketing approval for Merck, Sharp & Dohme’s (MSD; NYSE: MRK) oral drug Welireg (belzutifan) as a therapy for von Hippel-Lindau (VHL) disease-related renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastoma, and pancreatic neuroendocrine tumor (pNET) that do not require immediate surgical intervention.…
-
Medtronic Reports 5% Organic Revenue Growth in Q2 FY25 with Strong Portfolio Performance
•
US-Irish medical device company Medtronic (NYSE: MDT) has announced its financial results for the second quarter (Q2) of fiscal year 2025, which concluded on October 25, 2024. The company reported a total revenue of USD 8.403 billion for the period, marking a 5.0% increase on an organic basis. Cardiovascular Portfolio…
-
Pfizer and Flagship Pioneering Expand Partnership with Two New Biotechnology Agreements
•
The billion-dollar, multi-program partnership between US pharmaceutical giant Pfizer (NYSE: PFE) and bioplatform innovation company Flagship Pioneering, initiated in July 2023, has expanded with two new additions. Ampersand Biomedicines and Montai Therapeutics, both Flagship-founded biotechs, have entered into agreements to identify targeted molecules aimed at treating obesity and non-small cell…
-
Easton Pharmaceutical Secures NMPA Approval for Generic Jakavi and Urocit-K
•
Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced that it has received separate marketing approvals from the National Medical Products Administration (NMPA) for its generic versions of Incyte Corporation’s Jakavi(ruxolitinib) and Missionpharma’s Urocit-K(potassium citrate), marking a significant milestone for the company. Approval of Generic JakaviJakavi, a JAK inhibitor, is…
-
Innorna’s mRNA Drug IN015 Earns Orphan Drug Designation for PFIC Treatment
•
Shenzhen-based Innorna Co., Ltd, a leading platform company specializing in mRNA technology and LNP (lipid nanoparticle) delivery technology, has announced that it has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its investigational mRNA drug, IN015. The designation is for the treatment of progressive…
-
Kura Oncology and Kyowa Kirin Ink Licensing Deal for Menin Inhibitor Ziftomenib
•
US-based Kura Oncology, Inc. (NASDAQ: KURA) has entered into a licensing deal with Japan-headquartered Kyowa Kirin Co., Ltd. (TYO: 4151), granting Kyowa Kirin exclusive commercialization rights to Kura’s menin inhibitor ziftomenib outside of the United States. Kura retains the corresponding rights within the US. Financial Terms and MilestonesAccording to the…
-
Jiangsu Hengrui Receives NMPA Approval for HRS-6208 Solid Tumor Clinical Study
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from the National Medical Products Administration (NMPA) to commence a clinical study for its investigational drug HRS-6208 as a monotherapy for solid tumors. HRS-6208: A Selective Small Molecule InhibitorThe drug, a selective small molecule inhibitor with…
-
CR Pharma’s CR Sanjiu to Sell 51% Stake in Shenghuo for RMB 1.791 Billion
•
China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has announced a significant internal restructuring within its corporate structure. The company’s sub-subsidiary, China Resources Kunming Shenghuo Pharmaceutical CO., Ltd., also known as CR Sanjiu (SHE: 000999), is poised to sell its 51% stake in Shenghuo to another subsidiary of CR Pharma,…
-
InxMed’s Ifebemtinib Earns Breakthrough Therapy Designation for NSCLC Treatment in China
•
China-based InxMed (Nanjing) Co., Ltd has announced that the Center for Drug Evaluation of the National Medical Products Administration (NMPA) has granted a Breakthrough Therapy Designation (BTD) to its innovative small-molecule ifebemtinib (IN10018). The designation is for the use of ifebemtinib, a focal adhesion kinase (FAK) inhibitor, in combination with…
-
Novartis Expands Gene Therapy Portfolio with Acquisition of Kate Therapeutics
•
Swiss pharmaceutical company Novartis (NYSE: NVS) has announced the acquisition of US-based Kate Therapeutics, Inc., a pre-clinical biotech firm specializing in adeno-associated virus (AAV)-based gene therapies for muscle and heart diseases, for a substantial USD 1.1 billion. This strategic move allows Novartis to gain access to Kate’s pre-clinical gene therapy…
